The Harms of Psychedelics Need to Be Put Into Context

In November 2021, when the psychedelics company Compass Pathways released the top-line results of its trial looking at psilocybin in patients with treatment-resistant depression, the stock of the company plunged almost 30 percent. The dive was reportedly prompted by the somewhat-middling results of the research—but also because of the scattering of serious adverse events that occurred during the trial.

Amid the psychedelic renaissance, bringing up their potential harms has been somewhat of a taboo. The field, vilified for decades, has only just recently reentered the mainstream, after all. But as clinical trials get bigger—and

→ Continue reading at Wired - Science

More from author

Related posts

Advertisment

Latest posts

GM pauses sales of Chevy Blazer EV over software issues | CNN Business

New York CNN  —  GM has paused sales of its brand new Chevy Blazer EVs after some customers reported...

Crypto’s 2023 was marred by fraud and scandal. It was its best year ever | CNN Business

New York CNN  —  Crypto’s 14th year in existence was one marred by scandal, bankruptcy, fraud and regulatory squabbling....

The Tantalizing Mystery of the Solar System’s Hidden Oceans

The original version of this story appeared in Quanta Magazine.For most of humankind’s existence, Earth was the only known ocean-draped world, seemingly unlike any...